More importantly, further studies are needed to examine the potential of SIRT6 activators such as MDL-800/MDL-811 for treating aging-related vascular diseases, such as atherosclerosis, hypertension, and stroke in humans, followed by preclinical and clinical trials. This evidence concerns the gene SIRT6 and hypertensive disorder.